齐拉西酮与利培酮对精神分裂症患者生活质量的影响

目的探讨齐拉西酮与利培酮对精神分裂症患者生活质量的影响。方法将104例精神分裂症患者按人院顺序分随机分为两组各52例，研究组口服齐拉西酮治疗，对照组口服利培酮治疗，观察12w。于治疗前及治疗1w、3w、6w、12w末采用简明精神病量表，副反应量表评定临床疗效及不良反应，采用世界卫生组织编制的生存质量量表评定生活质量。结果两组治疗各时段简明精神病量表评分，均较治疗前呈持续性下降，差异有极显著性（P〈0．01）；同期两组间比较均无显著性差异（P〉0．05）。生存质量量表各维度评分均较治疗前呈持续性升高；同期研究组心理健康、社会关系、环境因素维度分均较对照组升高更显著（P〈0．05或0．01）。研究组不良反应发生率显著低于对照组（P〈0．05），治疗后各时点副反应量表评分均显著低于对照组（P均〈0．01）。结论齐拉西酮治疗精神分裂症疗效与利培酮相当，但提高患者的认知功能，改善生活质量的效果更为显著，不良反应较轻微，安全性更高，有利于患者的远期康复。

Influences of ziprasidone and risperidone on quality of life in schizophrenic

Objective To explore the influences of ziprasidone and risperidone on quality of life in schizophrenia. Methods 104 schizophrenics were randomly divided into two groups of 52 patients each according to admission order,research group took orally ziprasidone and control group did risperidone for 12 weeks. Before treatment and at the end of the 1st, 3rd, 6th and 12th week, clinical efficacies were assessed with the Brief Psychiatric Rating Scale （BPRS）, adverse reactions with the Treatment Emergent Symptoms Scale （TESS） and quality of life with the WHO Quality of Life-BREF （QOL-BREF）. Results After treatment, the total scores of th BPRS of both groups lowered continously compared with pretreatment,differences were very signifieant（P〈0.01） ; there were no significant differences in synchronization groups comparisons（P〉0.05）. All dimensions＇ scores of the QOL-BREF increased continously compared with pretreatment; mental health,social relation and environmental factor score increased rare significantly in the research than in the control in the corresponding time period（P〈0.05 or 0.01）. Incidences of adverse reactions were significantly lower（P〈0.05） in the research than in the control group, so were all timepoint scores of the TESS after treatment（all P〈0.01）. Conclusion Ziprasidone has therapeatic equivalence to risperidone in schizophrenia, especially in improving cognitive function and quality of life, mild adverse reactions,higher safety, and makes for patients＇ long-term rehabilitation.